Moreover, a study by Xiong et al showed that CAFs promote chemoresistance to taxane based therapy in prostate cancer cells by secreting ANGPTL4, which in turn binds to IQGAP1 activating the Raf-MEK-ERK-PGC1a axis. This evidence concerns the gene MAP2K7 and prostate cancer.